In regression analysis escalation of therapy was significantly associated with sustained benefit at 12 months (p=0.017), while concomitant immunomodulators, steroids and cumulative induction dose were not.

Conclusions

In this study, Ustekinumab provided sustained clinical benefit to almost half of patients with medically-refractory Crohn’s Disease. These data suggest that induction therapy with subcutaneous Ustekinumab may be an alternative to iv induction. The findings highlight that escalation of therapy is associated with sustained benefit at 12 months. As with anti-TNF therapy, dose optimisation appears to be critical in inducing and maintaining response with Ustekinumab.